Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC).
Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), J.M. Jürgensmeier, Darrell M. Wilson(Stanford Medicine), Laura A. Pike(Instituto do Câncer do Estado de São Paulo), Sara Morgan, P. M. Hoff, Jane Robertson(Cancer Research UK)
Cited by 7
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
|The Lancet Oncology|2012|526
Association of Hypoglycemia, Hyperglycemia, and Glucose Variability With Morbidity and Death in the Pediatric Intensive Care Unit
|PEDIATRICS|2006|359
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
|Annals of Oncology|2016|344
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303